Biologics in India: bridging the gap

Section 10(4)(ii)(D) of India’s Patents Act, 1970 mandates the disclosure of the source and geographical origin of biological material whenever it’s mentioned in a patent specification but not sufficiently described in it or made available to the public.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Novartis win blocks generics relitigating $7.8bn heart drug patent

22 January 2026 A district court judge shuts down a Novartis rival from reopening validity and infringement arguments over an Entresto patent.

Americas

Rooted rights: Lessons from plant patent infringement and invalidity cases

22 January 2026 From public use and foreign sales to the challenges of proving infringement, plant patents present unique legal opportunities—and pitfalls—for the agricultural industry, explain Bree Vculek, Gaby Longsworth, and Robert Millonig of Sterne Kessler.

Careers

Cadwalader global head among trio moving to Orrick

22 January 2026 Orrick, Herrington & Sutcliffe adds senior litigators with experience in patent, trade secret, copyright, trademark, and commercial disputes across life sciences and technology.

More features

Rooted rights: Lessons from plant patent infringement and invalidity cases

How AI will be shaped by legal and regulatory developments in 2026

Key EU and UK regulatory changes to watch for in 2026

Regeneron v Alvotech: The big impact

Beyond traditional IP: A comprehensive AI strategy for life sciences

Prosecuting bispecific antibody patents: A cookbook for patent chefs

Novo Nordisk ramps up semaglutide defence as generics lurk

Novo Nordisk India strategy suffers semaglutide patent setback

Biologics in India: bridging the gap

More on this story

Editor's picks

Editor's picks

More features